Viridian Therapeutics, Inc./DE Payments to Acquire Marketable Securities
Viridian Therapeutics, Inc./DE (VRDN) reported Payments to Acquire Marketable Securities of $67.38 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2021-08-12
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for the quarter ending 2021-06-30 was $10.73M.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for the quarter ending 2021-03-31 was $56.65M.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for the quarter ending 2020-12-31 was $81.81M.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for fiscal 2020 was $81.81M, a 150.25% increase from fiscal 2019.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for fiscal 2019 was $32.69M, a 47.66% decline from fiscal 2018.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for fiscal 2018 was $62.46M.
- Viridian Therapeutics, Inc./DE payments to acquire marketable securities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2021-06-30 | $10.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $67.38M 10-Q · filed 2021-08-12 | $149.19M derived: sum of 3 quarters · filed 2021-08-12 | $149.19M derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | $56.65M 10-Q · filed 2021-05-07 | $138.46M derived: sum of 2 quarters · filed 2021-05-07 | $138.46M derived: sum of 3 quarters · filed 2021-05-07 | $138.46M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-12-31 | $81.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $81.81M derived: sum of 2 quarters · filed 2021-03-26 | $81.81M derived: sum of 3 quarters · filed 2021-08-12 | $81.81M 10-K · filed 2021-03-26 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-08-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-08-12 | $3.96M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-05-07 | $3.96M derived: sum of 3 quarters · filed 2021-05-07 | $8.91M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $3.96M derived: sum of 2 quarters · filed 2021-03-26 | $8.91M derived: sum of 3 quarters · filed 2021-03-26 | $32.69M 10-K · filed 2021-03-26 |
| 2019-09-30 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $8.91M derived: sum of 2 quarters · filed 2020-11-12 | $32.69M 10-Q · filed 2020-11-12 | $56.55M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $4.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $28.73M 10-Q · filed 2020-08-05 | $52.58M derived: sum of 3 quarters · filed 2020-08-05 | $58.39M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $23.78M 10-Q · filed 2020-05-08 | $47.64M derived: sum of 2 quarters · filed 2020-05-08 | $53.45M derived: sum of 3 quarters · filed 2020-05-08 | $86.25M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $29.67M derived: sum of 2 quarters · filed 2020-03-13 | $62.46M derived: sum of 3 quarters · filed 2020-03-13 | $62.46M 10-K · filed 2020-03-13 |
| 2018-09-30 | $5.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $38.60M derived: sum of 2 quarters · filed 2019-11-08 | $38.60M 10-Q · filed 2019-11-08 | $38.60M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $32.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $32.80M 10-Q · filed 2019-08-08 | $32.80M derived: sum of 3 quarters · filed 2019-08-08 | $32.80M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-05-09 | $0.00 derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 10-K · filed 2019-03-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$3.01M derived: sum of 2 quarters · filed 2018-03-15 | $1.00M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.01M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $4.01M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |